Rodolfo Savitzky to succeed Toralf Haag as Lonza Group CFO
Rodolfo Savitzky appointed as new CFO for Lonza Group to succeed Toralf Haag who was appointed as CFO of the Voith Group in Germany
Lonza today announced that its Board of Directors appointed Rodolfo Savitzky as new CFO for Lonza. In this function he will be succeeding Toralf Haag, who after 11 years of service for Lonza accepted an offer from the Voith Group in Germany to become their new CFO and member of the Corporate Board of Management. The change will be effective as of 1 October 2016, when Rodolfo Savitzky will also succeed Toralf Haag as a member of the Lonza Executive Committee.
Rodolfo Savitzky (54) joined Lonza in March 2015 as Head of Finance & Controlling for the Pharma&Biotech segment. Previously he was CFO for the Animal Health Division of Novartis. Prior to this position, Rodolfo Savitzky held various financial management positions with increasing responsibilities at Novartis and Procter & Gamble. He holds an MBA in Finance/Economics from the University of Chicago. With his broad financial and industry background, his thorough understanding of Lonza’s strategic direction and his contributions to the Pharma&Biotech segment, Rodolfo Savitzky brings the necessary skillset to his new position.
Toralf Haag joined Lonza in 2005 as CFO and since then successfully led the financial organization of Lonza. He was significantly involved in the strategic development of Lonza and managed M&A projects successfully, as well as refinancing projects and the deleveraging of the company.
“I would like to take this opportunity to express my sincere thanks to Toralf for the services he has provided to this company. He led the finance department vigilantly and managed to steer the financial activities of Lonza successfully also through difficult times. Today he can hand over a financially solid company with a healthy balance sheet,” said Lonza CEO Richard Ridinger. “With Rodolfo Savitzky we found an excellent internal solution; and with the handover in early October, we can benefit from a well-planned and thought-through handover process, in which Toralf will continue to support a number of important projects.”
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance